Renalytix Plc
RNLX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -10.9% | 9.5% | -24.5% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 19.2% | 6.1% | -12.3% | 32.3% |
| R&D Expenses | $1 | $1 | $2 | $3 |
| G&A Expenses | $3 | $4 | $7 | $2 |
| SG&A Expenses | $3 | $4 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | -$3 | $3 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $4 | $6 | $6 | $9 |
| Operating Income | -$4 | -$6 | -$6 | -$8 |
| % Margin | -784.1% | -942.8% | -1,146.9% | -1,175.6% |
| Other Income/Exp. Net | -$1 | -$2 | -$2 | -$1 |
| Pre-Tax Income | -$5 | -$7 | -$8 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$8 | -$8 |
| % Margin | -905.7% | -1,207.2% | -1,447.3% | -1,196.8% |
| EPS | -0.08 | -0.1 | -0.16 | -0.17 |
| % Growth | 20% | 37.5% | 5.9% | – |
| EPS Diluted | -0.08 | -0.1 | -0.16 | -0.18 |
| Weighted Avg Shares Out | 53 | 69 | 48 | 47 |
| Weighted Avg Shares Out Dil | 53 | 69 | 49 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$6 | -$9 |
| % Margin | -772.4% | -932.6% | -1,134% | -1,252.2% |